Concord Biotech Limited issued a formal clarification to the stock exchanges dated February 09, 2026, addressing inquiries about a recent significant increase in trading volume for its securities. The company confirmed that it is fully compliant with all listing regulations and has not withheld any material, price-sensitive information. There are currently no impending announcements or corporate actions that require immediate disclosure.
Clarification on Unusual Trading Activity
Concord Biotech Limited responded on February 09, 2026, to an official query received from the BSE regarding a noticeable surge in the trading volume of the company’s securities across both exchanges recently.
Compliance Status Confirmed
The management, represented by Chairman & Managing Director Mr. Sudhir Vaid, affirmed that the company maintains strict compliance with all applicable listing regulations. This includes promptly informing the stock exchanges about any event or information that could potentially impact the company’s operations or financial performance.
Absence of Material Information
The primary clarification provided is that, as of the date of the letter, there is no undisclosed or price-sensitive information available that needs to be communicated to the exchanges. Furthermore, the company stated there are no pending announcements or corporate actions requiring immediate disclosure at this point in time.
Source: BSE
